Stability of gentamicin sulfate injection following unit dose repackaging

1976 ◽  
Vol 33 (12) ◽  
pp. 1254-1259
Author(s):  
Bruce Weiner ◽  
David J. McNeely ◽  
Ronica M. Kluge ◽  
Ronald B. Stewart
Keyword(s):  
1974 ◽  
Vol 110 (4) ◽  
pp. 638c-638
Author(s):  
T. E. Drake
Keyword(s):  

2000 ◽  
Vol 35 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Robert A. Quercia ◽  
Ronald Abrahams ◽  
C. Michael White ◽  
John D'Avella ◽  
Mary Campbell

A pharmacy-managed anemia program included distribution and clinical components, with the goal of making epoetin alpha therapy for hemodialysis patients more cost-effective. The Pharmacy Department prepared epoetin alpha doses for patients in unit-dose syringes, utilizing and documenting vial overfill. Pharmacists dosed epoetin alpha and iron (oral and intravenous) per protocol for new and established patients. Baseline data were obtained in 1994, one year prior to implementation of the program, and were re-evaluated in 1995 and 1998. Cost avoidance from utilization of epoetin alpha vial overfill in 1995 and 1998 was $83,560 and $91,148 respectively. In 1995 and 1998, cost avoidance from pharmacy management of anemia was $191,159 and $203,985 respectively. The total cost avoidance from 1995 through 1998 was estimated at $1,018,638. The number of patients with hematocrits under 31% decreased from 32% in 1994 to 21% and 14% in 1995 and 1998 respectively. We conclude that a pharmacy-managed anemia program for hemodialysis patients results in significant cost savings and better achievement of target hematocrits.


2021 ◽  
Vol 28 (4) ◽  
Author(s):  
Jitti Niyompanich ◽  
Piyachat Chuysinuan ◽  
Prasit Pavasant ◽  
Pitt Supaphol

Author(s):  
P Frémaux ◽  
A Fiedler ◽  
J Lelievre ◽  
M Le Bot ◽  
V Cogulet

2002 ◽  
Vol 59 (12) ◽  
pp. 1183-1188 ◽  
Author(s):  
Peter J. Ambrose ◽  
Frank G. Saya ◽  
Larry T. Lovett ◽  
Sandy Tan ◽  
Dale W. Adams ◽  
...  
Keyword(s):  

1995 ◽  
Vol 3 (3) ◽  
pp. 219-231 ◽  
Author(s):  
John R. Glowa ◽  
Francis H. E. Wojnicki ◽  
Dorota Matecka ◽  
John D. Bacher ◽  
Robert S. Mansbach ◽  
...  
Keyword(s):  

2021 ◽  
pp. 1-15
Author(s):  
Usha Luckock ◽  
Joanna Harnett ◽  
Rose Cairns

ABSTRACT Vitamin and mineral supplements (VMS) are widely available and commonly used. Little is known about patterns of poisoning exposures to VMS in the Australian population. We performed a retrospective study of calls to the New South Wales Poisons Information Centre (NSWPIC), July 2014-June 2019. NSWPIC is Australia’s largest PIC, taking approximately 100,000 calls/year (50% of Australian poisoning calls) from healthcare professionals and members of the public. We conducted additional analyses on iron exposures due to their high risk of acute toxicity. There were 10 944 VMS exposures reported to NSWPIC during the study period, increasing 9.6% per annum over a five year period (95%CI, 7.2 – 12.1%). Toddlers (1-4 years) accounted for 41.5% (4546) of cases. Agents most commonly involved were multivitamins (n=3610), Vitamin D (n=2080), iron (n=1533), and magnesium (n=804). In 17.7% (1934) of cases the call originated from hospital or the patient was referred to hospital by NSWPIC. Iron exposures increased by 14.0% per year (95%CI, 9.5 – 18.5%), and most were associated with high strength products (>45 mg elemental iron per unit dose, n=1036). Iron exposures were hospitalised in 38% of cases (n=583). We conclude that vitamin and mineral supplement exposures are increasing in Australia. Although most exposures can be managed at home, many required hospitalisation. Iron exposures are increasing and had higher rates of hospitalisation than other agents. Vitamin and mineral supplements are often considered safe and without the potential for adverse effects, highlighting the importance of public education into the potential risks of misuse of these products.


Sign in / Sign up

Export Citation Format

Share Document